PLLP

Across TCGA pan-cancer cohorts, PLLP mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLLP data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PLLP mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PLLP expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

GBM, PDAC, and CCRCC are the cancer types where PLLP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.339	0.721	.011	7	view →
PDAC	OS	Median	II,III,IV	0.834	0.219	.024	6	view →
CCRCC	OS	Tertile	II,III,IV	1.000	0.401	.036	2	view →
HNSC	OS	Median	All	0.620	0.801	.038	2	view →
LUAD	OS	Median	II,III,IV	0.864	0.998	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLLP–GBM (OS)

Open the GBM breakdown →